- Home
- NERV vs SYNX Comparison
NERV vs SYNX Comparison
Compare NERV & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- SYNX
- Stock Information
- Founded
- NERV 2007
- SYNX 2005
- Country
- NERV United States
- SYNX Israel
- Employees
- NERV N/A
- SYNX N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- SYNX
- Sector
- NERV Health Care
- SYNX
- Exchange
- NERV Nasdaq
- SYNX Nasdaq
- Market Cap
- NERV 10.3M
- SYNX 9.7M
- IPO Year
- NERV 2014
- SYNX 2024
- Fundamental
- Price
- NERV $1.78
- SYNX $1.79
- Analyst Decision
- NERV Hold
- SYNX
- Analyst Count
- NERV 1
- SYNX 0
- Target Price
- NERV $5.00
- SYNX N/A
- AVG Volume (30 Days)
- NERV 18.1K
- SYNX 26.7K
- Earning Date
- NERV 05-05-2025
- SYNX 05-21-2025
- Dividend Yield
- NERV N/A
- SYNX N/A
- EPS Growth
- NERV N/A
- SYNX N/A
- EPS
- NERV 0.19
- SYNX N/A
- Revenue
- NERV N/A
- SYNX $9,893,000.00
- Revenue This Year
- NERV N/A
- SYNX $52.34
- Revenue Next Year
- NERV N/A
- SYNX N/A
- P/E Ratio
- NERV $9.00
- SYNX N/A
- Revenue Growth
- NERV N/A
- SYNX 18.05
- 52 Week Low
- NERV $1.15
- SYNX $1.71
- 52 Week High
- NERV $3.69
- SYNX $6.49
- Technical
- Relative Strength Index (RSI)
- NERV 59.64
- SYNX 30.88
- Support Level
- NERV $1.52
- SYNX $1.74
- Resistance Level
- NERV $1.81
- SYNX $1.94
- Average True Range (ATR)
- NERV 0.17
- SYNX 0.16
- MACD
- NERV 0.04
- SYNX 0.02
- Stochastic Oscillator
- NERV 95.45
- SYNX 21.12
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat-proven. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both in training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, market and sell push-to-talk devices, communication controllers, and communication device cables and connectors.